Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

Abstract Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment approaches in MCL, most notably the class of Bruton's tyrosine kinase inhibitors (BTK...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, Udita Jindal, Isha Sharma, Lalit Sehgal, Narendranath Epperla
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2023-08-01
Ráidu:	Journal of Hematology & Oncology
Fáttát:	BTK inhibitor resistance Mantle cell lymphoma CAR T cell therapies Bispecific antibodies Antibody–drug conjugates
Liŋkkat:	https://doi.org/10.1186/s13045-023-01496-4
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!